Discussion
®, pneumothorax, IVH, pulmonary hemorrhage, RDS, sepsis, diabetes
PNEUMOTHORAX, PULMONARY HEMORRHAGE, SEPSIS, COMPLICATIONS, DIABETES
The prevalence of RDS is 45% [In this study, we compared a new and cost-effective surfactant produced in Iran with a relatively more expensive and inaccessible surfactant. Based on our results, there were no significant differences between frequencies of gender, type of delivery and diabetes in mothers in BLES and Beraksurf groups. In the present study, neonates treated with Beraksurf experienced the complications such as PDA, IVH, sepsis, pneumothorax, and pulmonary hemorrhage less frequently than those treated with BLES. From all these assessed complications, only pneumothorax and pulmonary hemorrhage caused significant statistical difference between the two groups. Also, the mortality rate in Beraksurf group was 17.2% and was lower than BLES group (31.3%), however, the The Beraksurf treatment in our study is a cost-effective and available surfactant; based on our results, its effect on RDS complications is similar to BLES. When compared with BLES, incidence risk of some complications such as pneumothorax and pulmonary hemorrhage in RDS patients is lower with this surfactant. BLES was first used in 1983; this Canadian surfactant is a powerful and effective drug in RDS treatment and is a fully natural human surfactant produced from amniotic fluid or biosynthetic materials. But, the Survanta is a natural corrected surfactant that is produced in some countries. In Iran this surfactant with the brand name Beraksurf® was produced by Tekzima pharmaceutical company. The chemical component of Beraksurf is similar to other Survanta and it is expected to be an effective surfactant with lower price and more availability.Some studies compared the non-Iranian Survanta with other surfactants (given the similarity of Iranian Survanta to Survanta manufactured in other countries). In a study conducted by Macooie et al. [